Conflict of interest among Italian medical oncologists: a national survey

Objectives To assess Italian medical oncologists’ opinion on the implications of conflict of interest (COI) on medical education, care and research, and to evaluate their direct financial relationships. Design National cross-sectional survey conducted between March and April 2017 among Italian oncologists. Setting Online survey sponsored by the Italian College of Medical Oncology Chiefs through its website. Participants Italian oncologists who filled out an anonymous questionnaire including 19 items and individual and working characteristics. Main outcome measure The proportion of medical oncologists perceiving COI as an outstanding issue and those receiving direct payments from industry. Results There were 321 respondents, representing 13% of Italian tenured medical oncologists. Overall, 62% declared direct payments from the pharmaceutical industry in the last 3 years. Sixty-eight per cent felt the majority of Italian oncologists have a COI with industry, but 59% suppose this is not greater than that of other specialties. Eighty-two per cent consider that most oncology education is supported by industry. More than 75% believe that current allocation of industry budget on marketing and promotion rather than research and development is unfair, but 75% consider it appropriate to receive travel and lodging hospitality from industry. A median net profit margin of €5000 per patient enrolled in an industry trial was considered appropriate for the employee institution. Sixty per cent agree to receive a personal fee for patients enrolled in industry trials, but 79% state this should be reported in the informed consent. Over 90% believe that scientific societies should publish a financial report of industry support. Finally, 79% disagree to being a coauthor of an article written by a medical writer when no substantial scientific contribution is made. Conclusions Among Italian oncologists COI is perceived as an important issue influencing costs, education, care and science. A more rigorous policy on COI should be implemented.

[1]  A. Blum,et al.  What Does ‘Unpaid Consultant’ Signify? A Survey of Euphemistic Language in Conflict of Interest Declarations , 2018, Journal of General Internal Medicine.

[2]  Vinay Prasad,et al.  Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval , 2017, JAMA internal medicine.

[3]  Deborah Cohen,et al.  Cancer drugs: high price, uncertain value , 2017, British Medical Journal.

[4]  H. Naci,et al.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 , 2017, British Medical Journal.

[5]  S. Chimonas,et al.  Bringing Transparency to Medicine: Exploring Physicians' Views and Experiences of the Sunshine Act , 2017, The American journal of bioethics : AJOB.

[6]  James D. Murphy,et al.  Types and Distribution of Payments From Industry to Physicians in 2015 , 2017, JAMA.

[7]  W. Stead The Complex and Multifaceted Aspects of Conflicts of Interest. , 2017, Journal of the American Medical Association (JAMA).

[8]  J. Fricker New NICE criteria for drug access. , 2017, The Lancet Oncology.

[9]  J. Wise Still too little transparency among guideline writers and others , 2017, British medical journal.

[10]  W. J. Boscardin,et al.  Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study , 2017, British Medical Journal.

[11]  T. Mackey,et al.  Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. , 2016, Journal of the National Cancer Institute.

[12]  C. Gridelli,et al.  The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Aaron P. Mitchell,et al.  Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. , 2016, JAMA oncology.

[14]  E. Klein,et al.  Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. , 2016, Multiple sclerosis and related disorders.

[15]  F. Gilardi,et al.  Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies’ websites , 2016, BMJ Open.

[16]  M. McCarthy PubMed is urged to include competing interest information in abstracts , 2016, British medical journal.

[17]  Suzanne M. Miller,et al.  Financial Concerns About Participation in Clinical Trials Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Sonya Cressman,et al.  A Time-Trend Economic Analysis of Cancer Drug Trials. , 2015, The oncologist.

[19]  Vinay Prasad,et al.  Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. , 2015, JAMA oncology.

[20]  J. Lenzer,et al.  Diverting attention from financial conflicts of interest , 2015, British medical journal.

[21]  P. Gøtzsche,et al.  Under-reporting of conflicts of interest among trialists: a cross-sectional study , 2015, Journal of the Royal Society of Medicine.

[22]  M. McCarthy US doctors earn speaking and consulting fees from drug companies that sponsor their research , 2014, British medical journal.

[23]  L. Wen Patients can’t trust doctors’ advice if we hide our financial connections with drug companies , 2014, BMJ : British Medical Journal.

[24]  T. Fojo,et al.  Cancer drugs in the United States: Justum Pretium--the just price. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Weijer,et al.  What do Canadians think about physician-pharmaceutical industry interactions? , 2013, Health policy.

[26]  D. Pfister The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Egleston,et al.  Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Edward S. Kim,et al.  Physician and stakeholder perceptions of conflict of interest policies in oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Laurance Makers of anticancer drugs are “profiteering,” say 100 specialists from around the world , 2013, British medical journal.

[30]  A. Abernethy,et al.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. , 2013, The Oncologist.

[31]  A. Flanagin,et al.  Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey , 2011, BMJ : British Medical Journal.

[32]  Natasha Das,et al.  Plagiarism: Why is it such a big issue for medical writers? , 2011, Perspectives in clinical research.

[33]  Andreas Lundh,et al.  Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study , 2010, PLoS medicine.

[34]  S. Joffe,et al.  Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Grande A national survey of physician-industry relationships. , 2007, The New England journal of medicine.

[36]  E. Emanuel,et al.  Patients' views on financial conflicts of interest in cancer research trials. , 2006, The New England journal of medicine.

[37]  L. Saltz Perspectives on Cost and Value in Cancer Care. , 2016, JAMA oncology.

[38]  Sergio Sismondo,et al.  Industry sponsorship and research outcome. , 2012, The Cochrane database of systematic reviews.